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BACKGROUND: In an earlier study, a 25-hydroxyvitamin D3 (25(OH)D) score calculated from known predictors of vitamin D status
significantly predicted plasma levels of 25(OH)D and the risk of colorectal cancer, but the influence of the 25(OH)D score on survival
after diagnosis is unknown.
MATERIALS AND METHODS: We prospectively examined the influence of post-diagnosis predicted 25(OH)D levels on mortality among
1017 participants in the Nurses’ Health Study and Health Professionals Follow-Up Study who were diagnosed with colorectal cancer
from 1986 to 2004. Colorectal cancer-specific and overall mortality according to quintiles of predicted 25(OH)D levels were
assessed. Cox proportional hazards models were used to calculate hazard ratios (HRs) adjusted for other risk factors of survival.
RESULTS: Higher predicted 25(OH)D levels were associated with a significant reduction in colorectal cancer-specific (P trend¼0.02)
and overall mortality (P trend¼0.002). Compared with levels in the lowest quintile, participants with predicted 25(OH)D levels in
the highest quintile had an adjusted HR of 0.50 (95% CI, 0.26–0.95) for cancer-specific mortality and 0.62 (95% CI, 0.42–0.93) for
overall mortality.
CONCLUSION: Higher predicted 25(OH)D levels after a diagnosis of colorectal cancer may be associated with improved survival.
Further study of the vitamin D pathway in colorectal cancer is warranted.
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The vitamin D hypothesis has received strong experimental support
over the past two decades on the basis of the almost ubiquitous
expression, in colon cancer cells, of vitamin D receptors (VDR)
(Meggouh et al, 1991; Vandewalle et al, 1994) and 1-a-hydroxylase
(Zehnder et al, 2001), which converts plasma 25-hydroxyvitamin D3
(25(OH)D) into 1,25-dihyroxycholecalciferol (1,25(OH)2D). Bind-
ing of VDR by 1,25(OH)2D leads to differentiation and apoptosis
(Vandewalle et al, 1995; Diaz et al, 2000), and inhibition of
proliferation (Scaglione-Sewell et al, 2000), angiogenesis (Iseki et al,
1999; Fernandez-Garcia et al, 2005), and metastatic potential (Evans
et al, 2000; Lamprecht and Lipkin, 2001).
The best indicator of vitamin D status is plasma 25(OH)D level,
as it reflects not only total vitamin D intake but also cholecalciferol
production in the skin from type B ultraviolet (UV-B) radiation
and hydroxylation of all sources of cholecalciferol in the liver.
Prospective studies have shown that higher baseline plasma levels
of 25(OH)D are associated with a significant reduction in the risk
of colorectal cancer (Garland et al, 1989; Braun et al, 1995; Tangrea
et al, 1997; Feskanich et al, 2004; Wactawski-Wende et al, 2006;
Wu et al, 2007). A meta-analysis of five epidemiological studies
found a 51% decrease in the risk of colorectal cancer associated
with high plasma 25(OH)D levels (Po0.0001) (Gorham et al,
2007). In contrast, the influence of vitamin D on survival of
patients with established colorectal cancer remains uncertain. In a
previous study, we found that higher pre-diagnosis plasma
25(OH)D levels were associated with a significant improvement
in overall survival among 304 colorectal cancer patients (Ng et al,
2008). However, this study was limited by the small number of
patients who had available 25(OH)D plasma levels, and relied on a
single measurement of 25(OH)D drawn at least 2 years before
cancer diagnosis.
To evaluate the impact of vitamin D status after a diagnosis of
colorectal cancer in a larger number of patients, we developed a
model to predict plasma 25(OH)D levels. This 25(OH)D score
takes into account the combined influence of the major
determinants of vitamin D status (race as a surrogate of skin
pigmentation, residential state as a surrogate of UV-B radiation
exposure, leisure-time physical activity as a surrogate of sunlight
exposure, adiposity, and dietary and supplementary vitamin D
intake). In previous analyses, the score was correlated with plasma
25(OH)D levels and was significantly associated with the risk of
developing colorectal cancer (Giovannucci et al, 2006). To assess
the influence of post-diagnosis vitamin D status on colorectal
cancer survival, we calculated the post-diagnosis 25(OH)D score
among 1017 patients participating in two ongoing prospective
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scohort studies, the Nurses’ Health Study (NHS) and the Health
Professionals Follow-up Study (HPFS).
MATERIALS AND METHODS
Study population
In 1976, the NHS was established when 121700 US female
registered nurses aged 30–55 years answered a questionnaire on
risk factors for cancer and cardiovascular disease (Belanger et al,
1978; Colditz et al, 1997). Every 2 years, participants receive
follow-up questionnaires to update information on the potential
risk factors and new disease diagnoses. Dietary information was
first collected in 1980 and is updated in alternate follow-up cycles.
Blood samples were provided by 32826 participants aged 43–70
years from 1989 to 1990.
In 1986, the HPFS was established when 51529 male dentists,
optometrists, osteopaths, podiatrists, pharmacists, and veterinar-
ians aged 40–75 years responded to a questionnaire on risk factors
for cancer, cardiovascular disease, and diabetes. A follow-up
questionnaire is sent to participants every 2 years requesting an
update on non-dietary exposures and medical history, with dietary
history updated every 4 years. Blood samples were provided by
18018 participants from 1993 to 1995.
This study was approved by the Human Subjects Committee at
Brigham and Women’s Hospital and the Harvard School of Public
Health in Boston, MA, USA. All participants provided informed
consent for questionnaire and blood data to be used in research
studies.
Identification of colorectal cancer
On each follow-up questionnaire, participants were asked
whether they had a diagnosis of colorectal cancer during
the previous 2 years. When a participant (or next of kin for
decedents) reported a diagnosis of colorectal cancer, we asked
permission to obtain hospital records and pathology reports, and
blinded study physicians reviewed and recorded information
on tumour characteristics. For non-respondents, we searched
the National Death Index to discover deaths and ascertain any
diagnosis of colorectal cancer that contributed to death. We estimate
that 96–97% of cases were identified through these methods
(Giovannucci et al, 1994, 2006).
Individuals in this analysis were participants with pathologically
confirmed colorectal adenocarcinoma diagnosed between 1986
(when physical activity was first assessed) and 2004.
Measurement of mortality
Participants in the study cohort were followed until death or 2006.
Ascertainment of deaths included reporting by family or postal
authorities, and names of persistent non-responders were searched
in the National Death Index (Sathiakumar et al, 1998). More than
98% of deaths have been identified by these methods (Stampfer
et al, 1984; Giovannucci et al, 2006).
Cause of death was assigned by blinded physicians. Colorectal
cancer-specific survival was defined as the time from diagnosis to
death from colorectal cancer. Overall survival was defined as the
time from diagnosis to death as a result of any cause.
Exposure assessment
Derivation of the 25(OH)D prediction score has been described
previously (Giovannucci et al, 2006). Briefly, linear regression was
performed on 1095 men in the HPFS who were free of diagnosed
cancer at the time of blood draw and who had available plasma
25(OH)D levels measured by radioimmunoassay (Hollis, 1997).
Race, geographic region, dietary vitamin D intake, body mass
index (BMI), and physical activity were identified as independent
predictors of plasma 25(OH)D levels. Using the predictors’
regression coefficients (Table 1), a 25(OH)D score was calculated
for each cohort member. The model was able to predict a wide
range of 25(OH)D levels, from 9 to 36ngml
 1. The mean actual
circulating level of 25(OH)D for men in the highest decile of
predicted 25(OH)D was 11ngml
 1 higher (95% CI, 9–13) than
that of men in the lowest decile (1ngml
 1¼2.496nmoll
 1).
To validate this model, a 25(OH)D score was calculated for an
independent sample of 542 men in HPFS who also had available
Table 1 Factors contributing to predictors of age-adjusted plasma
25(OH)D level from a multiple linear regression model of 1095 men in the
Health Professionals Follow-Up Study (Giovannucci et al, 2006)
Factor
Change in 25(OH)D
(ngml
 1)
Intercept 33.81
Race
White 0 (referent)
African American  5.31
Asian  5.49
Other  0.17
Residence
Northeast/Mid-Atlantic 0 (referent)
Midwest/West +1.61
South +2.56
Quintile of leisure-time physical activity (MET-hr per week)
a
5 0 (referent)
4  1.81
3  3.07
2  3.59
1  5.40
Body mass index (kgm
 2)
o22 0 (referent)
22–24.9  0.40
25–29.9  1.80
30–34.9  2.58
X35  3.44
Dietary vitamin D (IU per day)
X400 0 (referent)
300–399  1.39
200–299  1.04
100–199  2.85
o100  4.16
Supplementary vitamin D (IU per day)
b
X400 0 (referent)
200–399  0.71
1–199 +0.97
o1  0.83
Season of blood draw
c
Autumn (September, October, and November) 0 (referent)
Summer (June, July, and August)  0.74
Spring (March, April, and May)  4.83
Winter (December, January, and February)  5.42
Abbreviations: 25(OH)D¼25-hydroxyvitamin D3;h r ¼hour; IU¼international
units; MET¼metabolic equivalents.
aPhysical activity is used as a proxy for outdoor
activities, which will tend to increase solar UV-B exposure.
bNot statistically significant.
cSeason of blood draw was adjusted but not used in the predictive model because
season is a strong determinant of 25(OH)D level and reflects the time of blood draw,
but it is not a factor in determining long-term average between-person variation in
25(OH)D level.
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splasma 25(OH)D measurements (Giovannucci et al, 2006). The
actual plasma level rose across increasing deciles of predicted
25(OH)D (P trendo0.001), and the difference in the mean actual
25(OH)D level between extreme deciles was 10ngml
 1, similar to
the difference of 11ngml
 1 in the initial dataset. Finally, in a
separate analysis of 47800 men, a statistically significant inverse
association was observed between predicted 25(OH)D levels and
the risk of developing colorectal cancer (Giovannucci et al, 2006).
Predicted 25(OH)D levels were calculated for our study cohort
using the regression coefficients in Table 1 and extrapolating them
to women. Post-diagnosis 25(OH)D score was the primary
exposure variable, calculated using baseline race and geographic
region, and values of physical activity, BMI, and vitamin D intake
reported 1–4 years after colorectal cancer diagnosis (to avoid
assessment during the period of active cancer treatment). Scores
were divided into quintiles, with cut-offs determined separately for
each cohort. We also examined the influence of pre-diagnosis
predicted 25(OH)D levels, using values of physical activity, BMI, and
vitamin D intake from the questionnaire administered immediately
before diagnosis. If a response was missing, one previous assessment
was carried forward; else, the patient was not included.
Covariates
Prognostic factors known to influence cancer mortality were
extracted from the medical record, including age, stage, grade
of differentiation, tumour location, and year of diagnosis. In
addition, BMI, physical activity, and total energy-adjusted calcium
intake were taken from the questionnaire administered immedi-
ately before diagnosis. Race and season of diagnosis were also
evaluated, but not found to be confounding variables, and were
therefore excluded from the multivariable model. All analyses were
adjusted for the cohort.
Statistical analyses
Death from colorectal cancer was the primary end point, and death
from any cause was a secondary end point. The primary statistical
analysis used the two-tailed linear test for trend with predicted
25(OH)D level as a continuous variable, consistent with earlier
studies (Feskanich et al, 2004), to avoid the possibility of selecting
cut points with maximal P-values. To facilitate the display of our
results, predicted 25(OH)D levels were defined in quintiles. Cox
proportional hazards models were used to calculate hazard ratios
(HRs) of death, adjusted for other risk factors for cancer survival.
The HRs were calculated according to quintiles of predicted
25(OH)D levels, with the lowest quintile as the reference group.
The proportionality of hazards assumption for the effect of
predicted 25(OH)D level was satisfied by examining it as a time-
dependent covariate in the Cox model.
Colorectal cancer-specific and overall mortality by tertile of
predicted 25(OH)D levels were examined using Kaplan–Meier
curves and the log-rank test (Therneau and Grambsch, 2000).
Tertiles were used instead of quintiles for ease of graphical viewing.
Subgroup analyses were performed, and adjusted HRs and 95%
CIs for an increment of 10ngml
 1 of predicted 25(OH)D levels for
cancer-specific and overall mortality were reported. Tests of
interaction between predicted 25(OH)D levels and relevant
covariates were assessed by entering in the model the cross
product of predicted 25(OH)D level as a continuous variable with
the covariate as a continuous or binary variable. All analyses used
SAS software, version 9.1 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Among 1017 eligible participants, there were 283 deaths, 119 of
which were due to colorectal cancer. The median time of follow-up
of participants who were still alive was 116 months (range 41–238
months). The median predicted 25(OH)D level was 27.18ngml
 1
in NHS and 29.18ngml
 1 in HPFS. This pattern is consistent with
what we saw in our previous analysis of pre-diagnosis plasma
25(OH)D levels and colorectal cancer survival, in which circulating
25(OH)D concentrations were also slightly higher in men than
in women: median plasma 25(OH)D level was 27.1ngml
 1 in men
and 23.9 and 25.7ngml
 1 for two laboratory runs in women
(Ng et al, 2008). The difference in mean post-diagnosis predicted
25(OH)D levels between the highest and lowest deciles in this
study cohort was 10ngml
 1, which is similar to the difference in
mean actual circulating 25(OH)D levels across extreme deciles of
predicted 25(OH)D in the original and validation cohorts.
Baseline characteristics according to quintiles of post-diagnosis
predicted 25(OH)D levels are shown in Table 2. Overall,
participants with higher predicted 25(OH)D levels were more
likely to be of white race, have a lower BMI, report higher physical
activity, have higher calcium intake, and were more likely to be
diagnosed with colorectal cancer in the summer or autumn. Other
prognostic characteristics did not differ significantly between
quintiles.
Higher post-diagnosis predicted 25(OH)D levels were associated
with a significant reduction in colorectal cancer-specific and
overall mortality (Figure 1A and B, respectively, and Table 3). This
relationship remained largely unchanged after adjusting for other
predictors of cancer survival (Table 3). Compared with patients
with post-diagnosis 25(OH)D scores in the lowest quintile, those in
the highest quintile had an adjusted HR of 0.50 (95% CI, 0.26–0.95;
P trend¼0.02) for cancer-specific mortality and 0.62 (95% CI,
0.42–0.93; P trend¼0.002) for overall mortality.
We considered the possibility that the 25(OH)D score may be
acting as a surrogate for the causal factor, such as BMI or physical
activity, which are both in the prediction equation. We therefore
repeated our analyses after adjusting for BMI and physical activity.
When BMI was included, the significant relationship between post-
diagnosis 25(OH)D score and cancer-specific and overall mortality
did not change. The adjusted HR was 0.51 (95% CI, 0.26–0.99;
P trend¼0.04) for cancer-specific mortality and 0.62 (95% CI, 0.41–
0.94; P trend¼0.005) for overall mortality, comparing extreme
quintiles. Similarly, when we controlled for physical activity, we
continued to observe a benefit for higher post-diagnosis predicted
25(OH)D levels, with an adjusted HR of 0.44 (95% CI, 0.22–0.87;
P trend¼0.01) for cancer-specific mortality and 0.67 (95% CI, 0.44–
1.00; P trend¼0.02) for overall mortality. When both BMI and
physical activity were included in the model, the adjusted HR was
0.45 (95% CI, 0.22–0.91; P trend¼0.02) for cancer-specific mortality
and 0.66 (95% CI, 0.43–1.03; P trend¼0.03) for overall mortality.
Moreover, when both BMI and physical activity were included in
our model, the remaining components of the post-diagnosis
25(OH)D score that were not ‘accounted for’ were region of
residence, race, and dietary and supplemental vitamin D intake.
We therefore explored the impact of each of these individual
variables on mortality in our study cohort, and found that patients
who reported higher total vitamin D intake showed a trend
towards lower risk of death (P trend¼0.08). Compared with those
in the lowest quintile, patients in the highest quintile of vitamin D
intake had an adjusted HR of 0.72 (95% CI, 0.49–1.04) for overall
mortality.
We also adjusted for calcium intake in our models and found a
persistent significant association between post-diagnosis predicted
25(OH)D levels and survival. The adjusted HR was 0.44 (95% CI,
0.23–0.87; P trend¼0.008) for cancer-specific mortality and 0.56
(95% CI, 0.37–0.84; P trend¼0.0005) for overall mortality,
comparing extreme quintiles. Of note, the addition of race and
season of diagnosis to the multivariable model also did not change
the adjusted HRs for cancer-specific and overall mortality. When
race was added to the model, the adjusted HR comparing extreme
quintiles was 0.53 (95% CI, 0.28–1.02; P trend¼0.04) for cancer-
Vitamin D and colorectal cancer survival
KN get al
918
British Journal of Cancer (2009) 101(6), 916–923 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sspecific mortality and 0.65 (95% CI, 0.43–0.97; P trend¼0.004)
for overall mortality. When season of diagnosis was included,
the adjusted HR was 0.49 (95% CI, 0.26–0.94; P trend¼0.02)
for cancer-specific mortality and 0.63 (95% CI, 0.42–0.93;
P trend¼0.004) for overall mortality.
Given that lower levels of post-diagnosis predicted 25(OH)D
could reflect the presence of occult cancer or other major illness,
we excluded patients who died within 6 months of their post-
diagnosis assessment. We continued to observe significant
reductions in the risk of cancer-specific and overall mortality with
increasing post-diagnosis 25(OH)D scores, with participants in the
highest quintile having an adjusted HR of 0.50 (95% CI, 0.25–0.98;
P trend¼0.03) for cancer-specific mortality and 0.63 (95% CI,
0.42–0.95; P trend¼0.003) for overall mortality.
In a separate analysis, pre-diagnosis 25(OH)D scores were
calculated for colorectal cancer patients with available information
(n¼1955). Higher pre-diagnosis 25(OH)D scores were found to be
associated with a decrease in cancer-specific and overall mortality
(P trend¼0.03 and 0.01, respectively). When we adjusted for pre-
diagnosis predicted 25(OH)D levels as well as other predictors of
cancer survival in our model, higher post-diagnosis predicted
25(OH)D levels were still associated with a significant reduction in
both cancer-specific (P trend¼0.02) and overall (P trend¼0.008)
mortality, whereas the effect of pre-diagnosis predicted 25(OH)D
level was no longer significant.
We examined the influence of post-diagnosis 25(OH)D
scores across the other predictors of cancer mortality (Figure 2A
and B). Stratified analyses of cancer-specific and overall survival
Table 2 Baseline characteristics of cohort according to quintile of predicted 25(OH)D (n¼1017)
Predicted 25(OH)D (ngml
 1)
Characteristic Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P-value
No. of patients 204 202 205 203 203 —
Median predicted 25(OH)D
(ngml
 1)
a – NHS (n¼606)
23.3 (range 19.1–24.8) 25.7 (range 24.9–26.4) 27.2 (range 26.5–28.0) 28.6 (range 28.0–29.7) 31.0 (range 29.7–34.9) —
Median predicted 25(OH)D,
(ngml
 1)
a – HPFS (n¼411)
25.8 (range 21.6–26.8) 27.8 (range 27.0–28.4) 29.2 (range 28.5–29.9) 30.8 (range 29.9–31.5) 32.8 (range 31.5–36.9) —
Mean age at diagnosis (years) 65.6 (s.e. 0.6) 66.0 (s.e. 0.5) 65.8 (s.e. 0.6) 65.7 (s.e. 0.5) 65.3 (s.e. 0.5) 0.92
b
Stage (%) 0.95
c
I 3 33 03 43 43 4
II 28 30 25 30 32
III 23 25 26 22 21
I V 44243
Unknown 12 11 13 10 10
Grade of tumor differentiation (%) 0.65
c
Well differentiated 12 14 12 11 19
Moderately differentiated 59 58 58 60 57
Poorly differentiated 11 10 12 11 11
Unknown 18 18 18 18 13
Location of primary tumor (%) 0.43
c
Proximal colon 36 38 39 40 41
Distal colon 33 37 33 35 31
Rectum 22 22 23 19 24
Unknown 9 3 5 6 4
Year of diagnosis (%) 0.32
c
1986–1995 47 46 52 49 55
1996–2004 53 54 48 51 45
Season of diagnosis
d (%) 0.003
c
S u m m e r 3 02 73 23 12 3
Autumn 20 23 20 34 26
Winter 25 22 27 19 23
Spring 25 28 21 16 28
Race (%) o0.0001
c
White 89 93 95 98 95
Black 5 1 0 0 0
Other 6 6 5 2 5
Mean body mass index at
diagnosis (kgm
 2)
28.7 (s.e. 0.3) 27.3 (s.e. 0.3) 26.1 (s.e. 0.3) 25.0 (s.e. 0.2) 24.4 (s.e. 0.2) o0.0001
b
Median physical activity at
diagnosis (MET-hr per week)
e
5.3 (range 0–148.1) 8.4 (range 0–98.0) 12.9 (range 0–131.8) 15.4 (range 0–127.7) 23.0 (range 0–625.2) o0.0001
f
Median total energy-adjusted
calcium intake (mg)
e
786 (range 248–3446) 817 (range 260–3375) 930 (range 329–3192) 936 (range 239–2935) 1010 (range 346–
4496)
o0.0001
f
Abbreviations: 25(OH)D¼25-hydroxyvitamin D3;H P F S ¼Health Professionals Follow-up Study; hr¼hour; IU¼international units; MET¼metabolic equivalents;
NHS¼Nurses’ Health Study; No.¼number; s.e.¼standard error.
a1ngml
 1¼2.496nmoll
 1.
bP-value calculated using one-way analysis of variance.
cP-value calculated
using w
2-test.
dSummer defined as June, July, and August; autumn defined as September, October, and November; winter defined as December, January, and February; spring
defined as March, April, and May.
eAnalysis restricted to those participants with available information.
fP-value calculated using Kruskal–Wallis test.
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sshowed no significant interactions; the inverse relationship
between post-diagnosis predicted 25(OH)D levels and mortality
remained largely unchanged across most subgroups. Of note, there
was a trend towards a greater impact of higher post-diagnosis
25(OH)D scores on overall survival in patients diagnosed in the
winter or spring compared with those diagnosed in summer or
autumn (P interaction¼0.06).
DISCUSSION
Among patients with colorectal cancer, higher post-diagnosis
predicted 25(OH)D levels were associated with a significant
reduction in cancer-specific and overall mortality. This relation-
ship was evident even after excluding patients who died within 6
months of their post-diagnosis 25(OH)D assessment, and across
different subgroups of patients.
Previous studies have suggested an inverse relationship between
vitamin D and cancer incidence. Prospective observational studies
showed that higher plasma 25(OH)D levels are associated with a
significant reduction in risk of colorectal cancer (Garland et al,
1989; Braun et al, 1995; Tangrea et al, 1997; Feskanich et al, 2004;
Wactawski-Wende et al, 2006; Wu et al, 2007). In a prospective,
placebo-controlled trial of vitamin D and calcium supplementation
in 1179 women, a statistically significant decrease of 60% in
all-cancer risk (including colorectal cancer) was seen in the
intervention arm (Po0.03) (Lappe et al, 2007).
We have previously shown that higher pre-diagnosis plasma
levels of 25(OH)D are associated with a significant 48% reduction
in overall mortality (Ng et al, 2008). However, we only had a single
measurement of plasma 25(OH)D levels taken at a median of
6 years before diagnosis. Furthermore, only 304 patients had
plasma available for analysis. Therefore, to assess the influence of
vitamin D status after cancer diagnosis in a larger population, we
used a validated prediction score to estimate 25(OH)D levels after
colorectal cancer diagnosis. This score is a reasonable predictor of
circulating 25(OH)D levels, and is associated with cancer incidence
and mortality (Giovannucci et al, 2006).
There are several mechanisms through which vitamin D may
influence survival after a diagnosis of colorectal cancer. Binding of
VDR by 1,25(OH)2D leads to transcriptional activation and
repression of target genes, resulting in differentiation and apop-
tosis, and inhibition of proliferation and angiogenesis (reviewed by
Deeb et al, 2007). In vitro and in vivo data have shown growth
inhibition, and differentiation of colon carcinoma cell lines and
xenografts by administration of 1,25(OH)2D (Eisman et al, 1987;
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Figure 1 (A) Colorectal cancer-specific survival according to tertile of
post-diagnosis predicted 25(OH)D levels. (B) Overall survival according to
tertile of post-diagnosis predicted 25(OH)D levels.
Table 3 Age-adjusted and multivariate hazard ratios of death according to quintile of predicted 25(OH)D in the entire study cohort (n¼1017)
Predicted 25(OH)D
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
Variable
No./
event
HR
(95% CI)
No./
event
HR
(95% CI)
No./
event
HR
(95% CI)
No./
event
HR
(95% CI)
No./
event
HR
(95% CI) P-trend
a
Colorectal cancer-specific mortality
Age-adjusted
b 204/29 Referent 202/29 1.02 (0.61–1.70) 205/28 0.95 (0.56–1.59) 203/19 0.62 (0.35–1.10) 203/14 0.45 (0.24–0.84) 0.006
Multivariate
c 0.99 (0.58–1.68) 1.04 (0.61–1.78) 0.62 (0.34–1.11) 0.50 (0.26–0.95) 0.02
Overall mortality
Age-adjusted
b 204/64 Referent 202/71 1.13 (0.80–1.58) 205/62 0.96 (0.68–1.36) 203/44 0.62 (0.42–0.91) 203/42 0.57 (0.38–0.84) 0.0004
Multivariate
c 1.19 (0.85–1.68) 1.05 (0.74–1.50) 0.63 (0.43–0.94) 0.62 (0.42–0.93) 0.002
Abbreviations: 25(OH)D¼25-hydroxyvitamin D3;C I¼confidence interval; HR¼hazard ratio; No.¼number.
aCalculated by using predicted 25(OH)D as a continuous variable,
adjusted for cohort.
bHRs, 95% CIs, and P-values are adjusted for age at diagnosis (years).
cMultivariate HRs, 95% CIs, and P-values are adjusted for age at diagnosis (in years as a
continuous variable), gender (male or female), cancer stage (I–IV or unknown), grade of tumor differentiation (well-differentiated, moderately-differentiated, poorly-
differentiated, or unspecified/missing), location of primary tumor (proximal, distal, rectum, or unknown), and year of diagnosis (as a continuous variable).
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sGiuliano et al, 1991; Zhao and Feldman, 1993; Shabahang et al,
1994; Iseki et al, 1999), and rat models of colorectal cancer
maintained on a 1,25(OH)2D diet developed fewer metastases
compared with controls (Evans et al, 2000).
We found that season of diagnosis may modify the effect of
predicted 25(OH)D levels on overall mortality, with participants
diagnosed in the winter or spring showing a slightly greater
reduction in the risk of death. Perhaps the impact of higher
vitamin D levels is greater in the winter and spring, when sunlight
exposure is at a minimum. For example, a patient with colorectal
cancer with a high post-diagnosis 25(OH)D score, despite
decreased UV-B exposure in winter and spring, may have a
survival advantage over a patient with a low score in these seasons.
The strengths of our study include its prospective design, use of
a validated prediction score, data on many potential confounders,
and excellent follow-up rate. As participants were health profes-
sionals, the accuracy of self-reported data is likely to be high. To
our knowledge, this study is the first to examine colorectal cancer
survival by use of a comprehensive assessment of factors that
determine 25(OH)D level. The similarity of our findings for
survival based on one measurement of plasma 25(OH)D level and
those based on our predictor score indicates that each may provide
comparable information on long-term 25(OH)D level, the pre-
sumed factor of interest.
The most apparent limitation of our approach is the possibility
that our 25(OH)D score is acting as a surrogate for the causal
factor, such as BMI or physical activity, through alternative
mechanisms. Physical activity has previously been shown to be
associated with improved outcomes in colorectal cancer patients
(Meyerhardt et al, 2006a,b). In contrast, the data for BMI and
colorectal cancer survival is conflicting (Meyerhardt et al, 2008).
However, our results for predicted 25(OH)D levels did not change
when adjusted for BMI or physical activity, and no significant
interactions were observed. Moreover, when both BMI and
physical activity were included in our model, examination of the
remaining components of the post-diagnosis 25(OH)D score
revealed that patients who reported higher total vitamin D intake
showed a trend towards a lower risk of death. As dietary sources of
vitamin D account for only 10% of circulating 25(OH)D levels
(Adams et al, 1982), it is not unexpected that the finding is
bordered on significance. This lends further support to the ability
of our score to represent vitamin D status, and to our hypothesis
that higher total vitamin D status – rather than simply adiposity or
physical activity – is driving the significant association with
survival. Furthermore, there is evidence that calcium may have an
independent role in colorectal cancer pathogenesis (Wu et al, 2002;
McCullough et al, 2003; Norat and Riboli, 2003). As the vitamin D
pathway is intimately linked to calcium homoeostasis, we
controlled for calcium intake in our analyses and found that our
results did not change.
Although the 25(OH)D score had been developed and validated
extensively in our cohort of men (Giovannucci et al, 2006), we
recognise that the score has not been validated in women.
However, there are no data in the current literature to suggest
that the determinants of serum 25(OH)D differ between men and
women. Furthermore, when our results were stratified by gender,
similar HRs were obtained for men and women for both cancer-
specific and overall mortality, with no significant interactions
(see Figure 2A and B). Indeed, when post-diagnostic predicted
25(OH)D level was evaluated solely in the 606 women with
Female
Male
Adjusted HR (95% CI)
2.2
Stage I/II
Stage III/IV
Well-/mod-diff
Poorly diff
Dx 1986–1995
Dx 1996–2004
Dx summer/fall
Dx winter/spring
0.80
Pinteraction
0 2.6
0.86
0.43
0.30
0.25
0.66
0.56
0.25
0.19
0.25
Age  66 y
Age > 66 y
Ca  897 mg
Ca > 897 mg
1.8 1.4 1.0 0.6 0.2
Colon
Rectum
BMI  25.7
BMI > 25.7
<11.9 met-hr per wk
11.9 met-hr per wk
0.47
0.11
0.53
0.41
0.83
0.09
0.63
0.45
0.06
0.89
Pinteraction
Female
Male
Adjusted HR (95% CI)
1.6 1.4
Stage I/II
Stage III/IV
Well-/mod-diff
Poorly diff
Dx 1986–1995
Dx 1996–2004
Dx summer/fall
Dx winter/spring
0 1.8
Age  66 y
Age > 66 y
Ca  897 mg
Ca > 897 mg
1.2 1.0 0.8 0.6 0.4 0.2
Colon
Rectum
BMI  25.7
BMI > 25.7
<11.9 met-hr per wk
11.9 met-hr per wk
AB
Figure 2 (A) Adjusted hazard ratios (HR) and 95% confidence intervals (CI) for an increment of 10ngml
 1 of predicted 25(OH)D levels for colorectal
cancer-specific mortality across strata of various factors. Mod-diff, moderately differentiated; Dx, diagnosed; BMI, body mass index (kgm
 2); met, metabolic
equivalents; hr, hours; wk, week; Ca, calcium; mg, milligrams. (B) Adjusted HR and 95% CI for an increment of 10ngml
 1 of predicted 25(OH)D levels for
overall mortality across strata of various factors. BMI, body mass index (kgm
 2); Ca, calcium; Dx, diagnosed; hr, hours; met, metabolic equivalents; mg,
milligrams; Mod-diff, moderately differentiated; wk, week; y, years.
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scolorectal cancer, a significant association was found between
predicted 25(OH)D level and cancer-specific (adjusted HR 0.26;
95% CI, 0.10–0.72; P trend¼0.02) and overall mortality (adjusted
HR 0.48; 95% CI, 0.27–0.88; P trend¼0.003). Moreover, any
impression in the 25(OH)D score among women in our study
would bias results in that cohort tend towards the null.
We also cannot completely exclude the possibility that lower
levels of post-diagnosis predicted 25(OH)D reflect other occult
predictors for poor prognosis. However, our findings remained
unchanged after adjusting for potential risk factors of colorectal
cancer mortality. To minimise bias in the post-diagnosis predicted
25(OH)D level by the presence of occult cancer or other major
illness, we excluded patients who died within 6 months of their
post-diagnosis vitamin D assessment, and continued to observe a
positive impact of higher predicted 25(OH)D scores.
In this cohort, data on treatment were limited. Approximately
half of the participants had stage I or II disease, for which surgery
alone is often the standard of care. In addition, although there have
been changes in the chemotherapeutic treatment of colorectal
cancer during the timeframe under study, we adjusted for year of
diagnosis in our models. Furthermore, the fairly homogeneous
socioeconomic and educational makeup of this cohort likely
minimises any disparities in chemotherapy receipt (VanEenwyk
et al, 2002). The NHS and HPFS are composed exclusively of
working health professionals with extensive access to health
care; as such, differential access to state-of-the-art health care
among participants is likely minimised. Lastly, because this was an
observational rather than a randomised study, we cannot
definitively attribute our results to 25(OH)D levels; further support
for a causal role of higher vitamin D status on survival may require
a randomised placebo-controlled trial.
In conclusion, our data suggest that higher levels of predicted
25(OH)D after a diagnosis of colorectal cancer may be associated
with improved survival. Additional efforts to understand the
mechanisms through which the vitamin D pathway influences
colorectal carcinogenesis and cancer progression are warranted.
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